October 16th, 2014
ABT Molecular Imaging, manufacturer of a fully integrated cyclotron solution for Molecular Imaging, has raised $15 Million in financing, helping to accelerate global expansion of the U.S. based firm. A total of $10 Million of the financing round was provided by SWK Holdings Corporation and $5 Million was a follow-on of a Series C offering.
Peter Kingma, President and CEO of ABT stated today that “This infusion of capital is further affirmation of ABT’s unique proposition in the oncology market, and will enable us to access exciting new markets, and develop our technology platform to better match significant untapped customer needs”.
"SWK is very pleased to partner with ABT to support the commercialization of the company's Biomarker Generator platform with non-dilutive capital," said Brett Pope, CEO of SWK Holdings Corporation. "ABT's Biomarker Generator is an important innovation that will expand access of imaging drugs worldwide.”
About SWK Holdings Corporation
SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
About ABT Molecular Imaging, Inc.
ABT Molecular Imaging, Inc. designs, manufactures and distributes an affordable, small-footprint Biomarker Generator™ for PET imaging agents. The Biomarker Generator produces individual doses of sterile, quality-controlled contrast material on-demand, in a prepared syringe, for injection directly into a patient. ABT’s Biomarker Generator is opening global markets to PET by offering a fully-automated, affordable solution at the point-of-care.